Navigation Links
Painkillers Linked to Still More Problems

Two recent studies have offered still more evidence of the dangers linked with certain painkillers including kidney problems// in addition to the heart concerns that was already raised with the drug marketed as Vioxx.

One report from Brigham and Women's Hospital, and Harvard Medical School, Boston, said that an analysis of 114 studies that involved over 116,000 people showed that rofecoxib commonly known as Vioxx "was associated with increased renal and (heart) arrhythmia risks."

The reason as to why the drug would cause kidney damage is still unclear. In September 2004 Merck & Co Inc. withdrew Vioxx from the market after a three-year study revealed that it doubled the risk of heart attack and strokes in patients taking it for at least 18 months.

Another report from the University of Newcastle, New South Wales, Australia, following a review of 23 studies confirms the findings of an increased risk of heart problems with Vioxx that could be found "during the first 30 days of treatment in contrast to the the original suggestion that the vascular risk was only seen after 18 months."

Merck, however, facing more than 11,500 product liability lawsuits from people with claims of problems from Vioxx, has said that it still believes the data confirm the increased heart risk begins only after the medicine had been taken for 18 months.

The Australian analysis also found that celecoxib commonly sold as Celebrex and marketed by Pfizer Inc. was not associated with heart problems at a dose no greater than 200 milligrams a day.

Its review has also raised serious questions about the safety of diclofenac, an older (analgesic) drug marketed more in Europe than the United States.

The report added, "In conclusion ... diclofenac seems to share this risk and, unlike celecoxib, it appears to be harmful at commonly used doses. We believe there are grounds for reviewing its regulatory status."

The research details hav e been published in this week's Journal of the American Medical Association.

David Graham, a physician who works for the U.S. Food and Drug Administration said, "What does this all mean? First, rofecoxib (Vioxx) increases the risk of acute myocardial infarction at low and high doses." There is no initial 18-month period of immunity from risk."

He added that Celebrex "also increases (heart) risk at doses higher than 200 mg/d ... several other NSAIDs (non-steroidal anti-inflammatory drugs) increase risk, including ... diclofenac and meloxicam ... indomethacin and probably ibuprofen," while studies agree that naproxen is "neutral" for heart attack risk.

Graham added that for most patients with arthritis or other conditions requiring chronic pain relief "naproxen appears to be the safest NSAID choice from a cardiovascular perspective." Naproxen is commonly known as Aleve and marketed by Bayer Corp.
NLA
'"/>




Related medicine news :

1. Painkillers Do Not Shorten Dying Patients Lives
2. Painkillers may protect against Alzheimers disease
3. Painkillers may raise miscarriage risk
4. Painkillers Increase Risk of Miscarriage
5. In The Habit Of Taking Painkillers For Your Chronic Headache? Time To Switch Over
6. Aspirin Might Counter Side Effects of Cox-2 Painkillers
7. Painkillers Lead To Liver Failure
8. Study Advocates Use Of Oral Painkillers After Cesarean Section
9. Overdose of Opioid Painkillers Can Kill Pain and The Patient
10. UK Recommendations On Painkillers Flaunted
11. Painkillers—New and Old—Increase the Risk for Heart Attak
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology: